Host-directed antiviral therapy
Antiviral drugs have traditionally been developed by directly targeting essential viral
components. However, this strategy often fails due to the rapid generation of drug-resistant …
components. However, this strategy often fails due to the rapid generation of drug-resistant …
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human
liver. Expression is highly variable both between individuals and within individuals, owing to …
liver. Expression is highly variable both between individuals and within individuals, owing to …
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
R Griesel, G Maartens, M Chirehwa… - Clinical Infectious …, 2021 - academic.oup.com
Background Dolutegravir is associated with more weight gain than efavirenz. Loss-of-
function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we …
function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we …
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
H Bruckmueller, I Cascorbi - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies
M Biswas, N Sawajan, T Rungrotmongkol… - Frontiers in …, 2022 - frontiersin.org
Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19)
pandemic situations without establishing clinical effectiveness or tailoring safety. A …
pandemic situations without establishing clinical effectiveness or tailoring safety. A …
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub …
Objectives We evaluated the importance of ethnicity and pharmacogenetic variations in
determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two …
determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two …
Adverse neuropsychiatric events and recreational use of efavirenz and other HIV-1 antiretroviral drugs
Efavirenz is a highly effective HIV-1 antiretroviral; however, it is also frequently associated
with neuropsychiatric adverse events (NPAE) that include abnormal dreams, sleep …
with neuropsychiatric adverse events (NPAE) that include abnormal dreams, sleep …
High plasma efavirenz level and CYP2B6* 6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a …
G Yimer, W Amogne, A Habtewold… - The …, 2012 - nature.com
The objective of this study was to assess the incidence, timing and identify
pharmacogenetic, efavirenz (EFV) pharmacokinetic and biochemical predictors of EFV …
pharmacogenetic, efavirenz (EFV) pharmacokinetic and biochemical predictors of EFV …
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients
G Yimer, N Ueda, A Habtewold, W Amogne, A Suda… - PLoS …, 2011 - journals.plos.org
Background Implication of pharmacogenetic variations and efavirenz pharmacokinetics in
concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury …
concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury …